LBG
VRTX icon

Lloyds Banking Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Lloyds Banking Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-2,596
Closed -$291K – 398
2014
Q3 		$291K Buy
2,596
+1,635
+170% +$156K 0.08% 230
2014
Q2 		$90K Sell
961
-182,902
-99% -$12.8M 0.02% 348
2014
Q1 		$13M Buy
183,863
+131,092
+248% +$10.4M 0.12% 195
2013
Q4 		$3.92M Sell
52,771
-5,357
-9% -$373K 0.04% 348
2013
Q3 		$4.41M Buy
+58,128
New +$4.63M 0.05% 288

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Lloyds Banking Group's VRTX Position: Q4 2014 in Review

Lloyds Banking Group sold out of Vertex Pharmaceuticals (VRTX) in Q4 2014, closing a stake of 2,596 shares — an estimated $291K sold.

Lloyds Banking Group first reported a position in VRTX in Q3 2013 and held it in 5 quarters. The position peaked at $13M in Q1 2014. 475 funds tracked by Wall St. Rank hold VRTX as of Q4 2014.

  • Lloyds Banking Group reported no remaining Vertex Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Lloyds Banking Group sold 2,596 Vertex Pharmaceuticals shares in Q4 2014, an estimated $291K.
  • Lloyds Banking Group first reported a position in Vertex Pharmaceuticals in Q3 2013 and held it in 5 quarters.
  • Lloyds Banking Group's Vertex Pharmaceuticals position peaked at $13M in Q1 2014.
  • 475 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2014.

Based on Lloyds Banking Group's 13F filing for Q4 2014, filed 12 Feb 2015.